Naloxone Affordability Act of 2023
This bill requires the Government Accountability Office to study access to and affordability of naloxone (a medication that temporarily reverses opioid overdoses). The study must address matters related to out-of-pocket costs that consumers pay for naloxone and coverage for naloxone as an over-the-counter drug through Medicare, Medicaid, and private health insurance.
Historically, naloxone required a prescription and so was typically covered by health insurance. However, the Food and Drug Administration approved Narcan (a naloxone hydrochloride nasal spray) for use without a prescription on March 29, 2023, and health insurance does not generally cover over-the-counter medications.
Introduced in House
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line